Discontinuation of Antihyperlipidemic Drugs — Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?
- 27 April 1995
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 332 (17) , 1125-1131
- https://doi.org/10.1056/nejm199504273321703
Abstract
Discontinuation rates for drugs used to treat chronic conditions may affect the success of therapy. However, the discontinuation rates reported in clinical trials may not reflect those in primary care settings.Keywords
This publication has 37 references indexed in Scilit:
- Once-daily, extended-release gemfibrozil in patients with dyslipidemiaThe American Journal of Cardiology, 1993
- Prevention of restenosis by lovastatin after successful coronary angioplastyAmerican Heart Journal, 1991
- Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitusThe American Journal of Cardiology, 1990
- Efficacy and tolerability of lovastatin in a six-month study: Analysis by gender, age and hypertensive statusThe American Journal of Cardiology, 1990
- Compliance and chronic disease.Hypertension, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.Circulation, 1984
- Determinants of dropout rate among hypertensive patients in an urban clinicJournal of Community Health, 1979
- Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortalityJournal of Chronic Diseases, 1978
- The dropout problem in antihypertensive treatment: A pilot study of social and emotional factors influencing a patient's ability to follow antihypertensive treatmentJournal of Chronic Diseases, 1970